Novel aryl diketo-containing inhibitors of HIV-1 integrase

Drugs of the Future

Volumn 27, Issue 11, 2002, Pages 1101-1111

  Pais, Godwin C G ^a   Burke Jr , Terrence R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 1,3 PROPANEDIONE DERIVATIVE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; INDOLE DERIVATIVE; INDOLE DIKETO ACID; INTEGRASE; INTEGRASE INHIBITOR; L 708906; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; UNCLASSIFIED DRUG;

DRUG STRUCTURE; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 0036879016     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.11.703655     Document Type: Review

References (51)

1. De Clercq, E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J Med Chem 1995, 38: 2491-517.
2. Richman, D.D. HIV chemotherapy. Nature 2001, 410: 995-1001.
3. LaFemina, R.L., Schneider, C.L., Robbins, H.L. et al. Requirement of active human immunodeficiency virus type 1 integrase for productive infection of human T-lymphoid cells. J Virol 1992, 66: 7414-9.
4. Neamati, N., Sunder, S., Pommier, Y. Design and discovery of HIV-1 integrase inhibitors. Drug Discov Today 1997, 2: 487-98.
5. Pommier, Y., Marchand, C., Neamati, N. Retroviral integrase inhibitors year 2000: Update and perspectives. Antiviral Res 2000, 4: 139-48.
6. Pommier, Y., Neamati, N. Inhibitors of human immunodeficiency virus integrase. Adv Virus Res 1999, 52: 427-58.
7. Neamati, N., Marchand, C., Pommier, Y. HIV-1 integrase inhibitors: Past, present and future. Adv Pharmacol 2000, 49: 147-65.
8. Farnet, C.M., Wang, B.B., Lipford, J.R., Bushman, F.D. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc Natl Acad Sci USA 1996, 93: 9742-7.
9. Goldgur, Y., Craigie, R., Cohen, G.H. et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc Natl Acad Sci USA 1999, 96: 13040-3.
10. Hazuda, D.J., Felock, P., Witmer, M. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287: 646-50.
11. Grobler, J.A., Stillmock, K., Hu, B. et al. Diketo acid inhibitor mechanism and HIV-1 integrase implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA 2002, 99: 6661-6.
12. Farnet C.M., Bushman, F.D. HIV cDNA integration: Molecular biology and inhibitor development. AIDS 1996, 10: S3-11.
13. Asante-Appiah, E., Skalka, A-M. Molecular mechanism in retrovirus DNA integration. Antiviral Res 1997, 36: 139-56.
14. Pommier, Y., Pilon, A., Bajaj, K., Mazumdar, A., Neamati, N. HIV-1 integrase as a target for antiviral drugs. Antiviral Chem Chemother 1997, 8: 463-83.
15. Hansen, M.S., Carteau, S., Hoffmann, C., Li, L., Bushman, F.D. Retroviral cDNA integration: Mechanism, applications and inhibition. Genet Eng 1998, 20: 41-61.
16. Robinson, W.E. Jr. HIV integrase: The next target? Infect Med 1998, 15: 129-37.
17. Young, S.D. Inhibition of HIV-1 integrase by small molecules: The potential for a new class of AIDS chemotherapeutics. Curr Opin Drug Discov Dev 2001, 4: 402-10.
18. Nair, V. HIV integrase as a target for antiviral chemotherapy. Rev Med Virol 2002, 12: 179-93.
19. Condra, J.H., Miller, M.D., Hazuda, D.J., Emini, E.A. Potential new therapies for the treatment of HIV-1 infection. Annu Rev Med 2002, 53: 541-55.
20. Pluymers, W.D., De Clercq, E., Debyser, Z. HIV-1 integration as a target for antiretroviral therapy: A review. Curr Drug Targets-Infect Disord 2001, 1: 133-49.
21. Pani, A., Marongiu, M.E. Anti-HIV-1 integrase drugs: How far from shelf? Curr Pharm Des 2000, 6: 569-84.
22. Neamati, N. Structure based HIV-1 integrase inhibitor design: A future perspective. Expert Opin Invest Drugs 2001, 10: 281-96.
23. Neamati, N. Patented small molecule inhibitors of HIV-1 integrase: A 10-year saga. Expert Opin Ther Patents 2002, 12: 709-24.
24. Williams, H.W.R., Eichler, E., Randall, W.C. et al. Inhibitors of glycolic acid oxidase. 4-Substituted 2,4-dioxobutanoic acid derivatives. J Med Chem 1983, 26: 1196-200.
25. Tomassini, J., Selnick, H., Davies, M.E. et al. Inhibition of CAP (M(7)GPPPXM)-dependent endonuclease of influenzavirus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 1994, 38: 2827-37.
26. Wai, J.S., Egbertson, M.S., Payne, L.S. et al. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem 2000, 43: 4923-6.
27. Pais, G.C.G., Zhang, X., Marchand, C. et al. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. 1. J Med Chem 2002, 45: 3184-94.
28. Zhang, X., Pais, G.C.G., Svarovskaia, E.S. et al. Azido-containing aryl β-diketo acid HIV-1 integrase inhibitors. Bioorg Med Chem Lett, in press.
29. Marchand, C., Zhang, X., Pais, G.C.G. et al. Structural determinants for HIV-1 integrase inhibition by β-diketo acids. J Biol Chem 2002, 277: 12596-603.
30. Espeseth, A.S., Felock, P., Wolfe, A. et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000, 97: 11244-9.
31. Young, S.D., Egbertson, M., Payne, L.S. et al. (Merck & Co., Inc.; Tularik, Inc.). HIV integrase inhibitors. PCT Int Appl 1999, WO-99/62520.
32. Young, S.D., Wai, J.S., Embrey, M.W., Fisher, T.E. (Merck & Co., Inc.). HIV integrase inhibitors. PCT Int Appl 1999, WO-99/62897.
33. Selnik, H.G., Hazuda, D.J., Egbertson, M. et al. (Merck & Co., Inc.; Tularik, Inc.). HIV integrase inhibitors. PCT Int Appl 1999, WO-99/62513.
34. Wolfe, A.A., Felock, P.J., Hastings, J.C., Blau, C.U., Hazuda, D.J. The role of manganese in promoting multimerization and assembly of human immunodeficiency virus type 1 integrase as a catalytically active complex on immobilized long terminal repeat substrates. J Virol 1996, 70: 1424-32.
35. Farnet C.M., Bushman, F.D. HIV-1 cDNA integration: Requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell 1997, 88: 483-92.
36. Fujishita, T., Yoshinaga, T., Yamaguchi, H. (Shionogi & Co., Ltd.). Indole derivatives with antiviral activity. PCT Int Appl 1999, WO-99/50245.
37. Walker, M.A., Johnson, T.D., Meanwell, N.A., Banville, J. (Bristol-Myers Squibb Co.). HIV integrase inhibitors. PCT Int Appl 2001, WO-01/96283.
38. Walker, M.A., Johnson, T.D., Kim, O.A. (Bristol-Myers Squibb Co.). HIV integrase inhibitors. PCT Int Appl 2001, WO-01/98248.
39. Payne, L.S., Tran, L.O., Zhuang, L.H. et al. (Merck & Co., Inc.; Tularik, Inc.). 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof. PCT Int Appl 2001, WO-01/00578.
40. Sato, A., Yamaguchi, H. et al. (Shionogi & Co., Ltd.). Medicinal compositions containing propenone derivatives. PCT Int Appl 2001, WO-96329.
41. Yoshinaga, T., Sato, A., Fujishita, T., Fujiwara, T. In vitro activity of a new HIV-1 integrase inhibitor in clinical development. 9th Conf Retroviruses Opportunistic Infect (Feb 24-28, Seattle) 2002, Abst 8.
42. Fujishita, T., Yoshinaga, T., Satao, A. (Shionogi & Co., Ltd.). Aromatic heterocycle compounds having HIV integrase inhibiting activities. PCT Int Appl 2000, WO-00/39086.
43. Kawasuji, T., Yoshinaga, T. (Shionogi & Co., Ltd.). Integrase inhibitors containing aromatic heterocyclic derivatives. PCT Int Appl 2001, WO-01/17968.
44. Kiyama, R., Kawasuji, T. (Shionogi & Co., Ltd.). Inhibitor for enzyme having two divalent metal ions as active centers. PCT Int Appl 2001, WO-01/95905.
45. Young, S.D., Anthony, N., Wai, J., Fisher, T. et al. Discovery of a potent HIV integrase inhibitor with potential clinical utility. 5th Int Workshop HIV Drug Resistance Treatment Strategies (Seville) 2002.
46. Anthony, N.J., Gomez, R.P., Young, S.D. et al. (Merck & Co., Inc.). Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors. PCT Int Appl 2002, WO-02/30930, WO-02/30931.
47. Harrison, R.W., Skalka, A.M. (Thomas Jefferson Univ.). Symmetric inhibitors of HIV integrase, mammalian topoisomerase and serine protease. PCT Int Appl 2002, WO-02/02516.
48. Sauvé, G., Yelle, J. (Pharmacor Inc.). Hydroxyphenyl derivatives with HIV integrase inhibitory properties. US6362165; 2002, PCT Int Appl WO-00/59867, 2000.
49. N'Zemba, B.M., Sauvé, G., Sevigny, G., Yelle, J. (Pharmacor Inc.). Aromatic derivatives with HIV integrase inhibitory properties. PCT Int Appl 20002, WO-02/26697.
50. Bell, I.M., Guare, J.P. Jr., Hazuda, D.J., Munson, P.M., Thompson, W.J., Vacca, J.P. (Merck & Co., Inc.). Benzodiazepine hydrazide derivatives as inhibitors of HIV integrase. PCT Int Appl 1998, WO-98/18473.
51. Melek, M., Jones, J.M., O'Dea, M.H. et al. Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proc Natl Acad Sci USA 2002, 99: 134-7.